Home > ACMD Methoxetamine report.

Advisory Council on the Misuse of Drugs. [Home Office UK] (2012) ACMD Methoxetamine report. London: Home Office. 20 p.

[img]
Preview
PDF (methoxetamine report) - Published Version
437kB

Report from the ACMD to the UK Home Secretary about methoxetamine.

The chemical structure of methoxetamine bears a close resemblance to that of both ketamine and phencyclidine (PCP, „Angel Dust‟, a class A drug), which both produce well-documented and serious adverse effects following both acute and chronic usage.

Users report that the effects of methoxetamine are similar to those of ketamine, however, some users report that the effects are of longer duration.The harmful effects reported include severe dissociation, cardiovascular symptoms, paranoid thoughts and unpleasant hallucinations.

The ACMD considers, from the available evidence, that the harms of methoxetamine are commensurate with Class B, of the UK Misuse of Drugs Act (1971); and it should be scheduled under Schedule I of the Misuse of Drugs Regulations (2001) (having no known recognised medicinal use).


Item Type:Evidence resource
Publication Type:Other
Drug Type:New psychoactive substance
Intervention Type:AOD disorder
Source:Home Office UK
Date:October 2012
Pages:20 p.
Publisher:Home Office
Corporate Creators:Advisory Council on the Misuse of Drugs
Place of Publication:London
EndNote:View
Accession Number:HRB (Electronic Only)
Related URLs:
Subjects:L Social psychology and related concepts > Legal availability or accessibility
B Drugs and alcohol substances > New (novel) psychoactive substances
VA Geographic area > Europe > United Kingdom

Repository Staff Only: item control page